A new S curve in PCI: Devices that Actively Adapt to Vascular Physiology

View
Event Information

Event Topic:
A new S curve in PCI: Devices that Actively Adapt to Vascular Physiology

Date/Time:
Date(s) - 11/28/17
8:30 am - 10:00 am

Event Location:
Sunnyvale City Council Chambers- 456 West Olive Ave., Sunnyvale,

Speaker Information

Event Speaker:
Vinayak Bhat

Event Speaker Title:
President and Chief Operating Officer

Event Speaker Company:
Elixir Medical

Event Speaker Bio:

Dr. Vinayak Bhat serves as the President & Chief Operating Officer of Elixir Medical. Dr. Bhat previously served as the Vice President & General Manager of DES Division of Avantec Vascular Corporation, a subsidiary of Goodman Co. Ltd., a Nagoya, Japan based medical product company. Dr. Bhat joined Avantec as Director of R&D, and was part of the management group which secured the sale of the company to Goodman Co. Ltd. in 2002. He also held several research and management positions within the Stent Business Unit of Guidant Corporation (currently Abbott Vascular). Dr. Bhat is an inventor or co-inventor on 40 US and EU patents and has over 25 pending applications. He also has 15 peer-reviewed publications and book chapters. Dr. Bhat holds a Bachelor’s degree in Chemical Engineering from University of Bombay, India, Masters in Biochemical Engineering and Ph.D. in Biomedical Engineering from Duke University, North Carolina.

Event Details

Cost:
$0

Event Details:
The talk will provide an overview of device development in percutaneous coronary intervention, from coronary angioplasty to fully bioresorbable scaffolds. The presentation will focus on a new generation of innovative devices developed by Elixir Medical, that are designed to actively adapt to the changing needs of vascular physiological and work in harmony with the artery to heal the diseased artery. These devices return the pulsatile motion of a beating coronary artery and demonstrate adaptive vascular remodeling that is observed in normal physiologic state. The devices have potential to provide clinical benefits in range of indications from cardiovascular to peripheral vascular diseases.